Analyst consensus rating
Contineum Therapeutics Analyst Rating: Strong Buy
CTNM is rated Strong Buy by 7 analysts with a $23.43 target. As of 2026-08-27.
Direct answer
Contineum Therapeutics's consensus rating is Strong Buy.
7 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $23.43.
Forecast evidence checked August 27, 2026.
Get free Contineum Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $17.02
- Average price target
- $23.43
- High price target
- $28.00
- Low price target
- $18.00
- Low target gap
- +5.8%
- Target upside
- +37.7%
- High target gap
- +64.5%
- Target range width
- 58.8%
- Consensus rating
- Strong Buy
- Analysts
- 7
- Evidence date
- August 27, 2026
- Valid through
- September 3, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Contineum Therapeutics?
Contineum Therapeutics has a verified Strong Buy consensus. The same dataset has an average price target of $23.43.
How far are Contineum Therapeutics's low and high targets from the recorded price?
The low target implies +5.8%, while the high target implies +64.5%.
How many analysts are included in Contineum Therapeutics's consensus?
The verified consensus includes 7 analysts.
How is Contineum Therapeutics's target upside or downside calculated?
The average target of $23.43 is divided by the recorded price of $17.02, then one is subtracted to produce +37.7%. This does not guarantee a future return.
When was Contineum Therapeutics's analyst forecast verified?
The data was verified on 2026-08-27. The dataset is valid through 2026-09-03.